{"transactions":[{"id":4618117,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-09-15T20:30:04.000Z","date":"2026-09-14","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":22.65,"value":226500.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 163,352 ordinary shares subject to restricted stock unit awards that remain subject to vesting."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects the prior transfer of 608,779 ordinary shares previously reported as indirectly beneficially owned by the Reporting Person.  Such ordinary shares were previously held of record by Stichting Administratiekantoor EPNAP for the benefit of the Reporting Person."}],"balance_after":792923,"source":{"system":"sec-edgar","filing":"0001193125-26-391985","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526391985/ownership.xml","form_type":"4"}},{"id":739876,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T20:31:53.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The entire option award shall vest on the earlier of:  (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date."}],"balance_after":22000,"derivative":{"exercise_price":15.48,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001573785-26-000003","document":"form4-06122026_080647.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000157378526000003/form4-06122026_080647.xml","form_type":"4"}},{"id":874641,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option (right to buy)","published_at":"2026-03-02T23:08:05.000Z","date":"2026-03-02","kind":"exercise","planned":false,"acquired":false,"shares":443707,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is EUR 1.16392."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted on November 22, 2022 to replace options originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 25% of the shares underlying the options vested on August 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":239267,"derivative":{"expiration_date":"2031-07-06","underlying":"Ordinary Shares","underlying_shares":443707},"source":{"system":"sec-edgar","filing":"0001193125-26-085947","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526085947/ownership.xml","form_type":"4"}},{"id":874640,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-03-02T23:08:05.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":443707,"price":33.25,"value":14753257.75,"ownership":{"direct":true},"balance_after":174144,"source":{"system":"sec-edgar","filing":"0001193125-26-085947","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526085947/ownership.xml","form_type":"4"}},{"id":874639,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-03-02T23:08:05.000Z","date":"2026-03-02","kind":"exercise","planned":false,"acquired":true,"shares":443707,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price of the option is EUR 1.16392."}],"balance_after":617851,"source":{"system":"sec-edgar","filing":"0001193125-26-085947","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526085947/ownership.xml","form_type":"4"}},{"id":879919,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option (right to buy)","published_at":"2026-02-27T02:40:55.000Z","date":"2026-02-26","kind":"exercise","planned":true,"acquired":false,"shares":183332,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is EUR 1.16392."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The option was granted on November 22, 2022 to replace options originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 25% of the shares underlying the options vested on August 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":682974,"derivative":{"expiration_date":"2031-07-06","underlying":"Ordinary Shares","underlying_shares":183332},"source":{"system":"sec-edgar","filing":"0001193125-26-078718","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526078718/ownership.xml","form_type":"4"}},{"id":879918,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option (right to buy)","published_at":"2026-02-27T02:40:55.000Z","date":"2026-02-25","kind":"exercise","planned":true,"acquired":false,"shares":58253,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is EUR 1.16392."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The option was granted on November 22, 2022 to replace options originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 25% of the shares underlying the options vested on August 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":866306,"derivative":{"expiration_date":"2031-07-06","underlying":"Ordinary Shares","underlying_shares":58253},"source":{"system":"sec-edgar","filing":"0001193125-26-078718","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526078718/ownership.xml","form_type":"4"}},{"id":879917,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option (right to buy)","published_at":"2026-02-27T02:40:55.000Z","date":"2026-02-24","kind":"exercise","planned":true,"acquired":false,"shares":64708,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is EUR 1.16392."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The option was granted on November 22, 2022 to replace options originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 25% of the shares underlying the options vested on August 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":924559,"derivative":{"expiration_date":"2031-07-06","underlying":"Ordinary Shares","underlying_shares":64708},"source":{"system":"sec-edgar","filing":"0001193125-26-078718","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526078718/ownership.xml","form_type":"4"}},{"id":879916,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-02-27T02:40:55.000Z","date":"2026-02-26","kind":"sale","planned":true,"acquired":false,"shares":17924,"price":34.44,"value":617302.56,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.35 to $34.82 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F9","text":"The amount reported in Column 5 reflects the transfer of 285,715 ordinary shares from the Reporting Person to the Michael H. Davidson 2026 Grantor Retained Annuity Trust (the \"GRAT\") on February 26, 2026, which transfer was exempt from Section 16 pursuant to Rule 16a-13 under the Securities Exchange Act of 1934. The Reporting Person is the sole annuitant and trustee of the GRAT."}],"balance_after":174144,"source":{"system":"sec-edgar","filing":"0001193125-26-078718","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526078718/ownership.xml","form_type":"4"}},{"id":879915,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-02-27T02:40:55.000Z","date":"2026-02-26","kind":"sale","planned":true,"acquired":false,"shares":165408,"price":33.63,"value":5562671.04,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.34 to $34.33 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":477783,"source":{"system":"sec-edgar","filing":"0001193125-26-078718","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526078718/ownership.xml","form_type":"4"}},{"id":879914,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-02-27T02:40:55.000Z","date":"2026-02-26","kind":"exercise","planned":true,"acquired":true,"shares":183332,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price of the option is EUR 1.16392."}],"balance_after":643191,"source":{"system":"sec-edgar","filing":"0001193125-26-078718","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526078718/ownership.xml","form_type":"4"}},{"id":879913,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-02-27T02:40:55.000Z","date":"2026-02-25","kind":"sale","planned":true,"acquired":false,"shares":1300,"price":36.68,"value":47684.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.58 to $36.74 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":459859,"source":{"system":"sec-edgar","filing":"0001193125-26-078718","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526078718/ownership.xml","form_type":"4"}},{"id":879912,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-02-27T02:40:55.000Z","date":"2026-02-25","kind":"sale","planned":true,"acquired":false,"shares":10436,"price":35.96,"value":375278.56,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.57 to $36.55 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":461159,"source":{"system":"sec-edgar","filing":"0001193125-26-078718","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526078718/ownership.xml","form_type":"4"}},{"id":879911,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-02-27T02:40:55.000Z","date":"2026-02-25","kind":"sale","planned":true,"acquired":false,"shares":46517,"price":35.11,"value":1633211.87,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.57 to $35.56 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":471595,"source":{"system":"sec-edgar","filing":"0001193125-26-078718","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526078718/ownership.xml","form_type":"4"}},{"id":879910,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-02-27T02:40:55.000Z","date":"2026-02-25","kind":"exercise","planned":true,"acquired":true,"shares":58253,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price of the option is EUR 1.16392."}],"balance_after":518112,"source":{"system":"sec-edgar","filing":"0001193125-26-078718","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526078718/ownership.xml","form_type":"4"}},{"id":879909,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-02-27T02:40:55.000Z","date":"2026-02-24","kind":"sale","planned":true,"acquired":false,"shares":3161,"price":36.46,"value":115250.06,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.43 to $36.50 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":459859,"source":{"system":"sec-edgar","filing":"0001193125-26-078718","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526078718/ownership.xml","form_type":"4"}},{"id":879908,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-02-27T02:40:55.000Z","date":"2026-02-24","kind":"sale","planned":true,"acquired":false,"shares":61547,"price":36.13,"value":2223693.11,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.43 to $36.42 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":463020,"source":{"system":"sec-edgar","filing":"0001193125-26-078718","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526078718/ownership.xml","form_type":"4"}},{"id":879907,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-02-27T02:40:55.000Z","date":"2026-02-24","kind":"exercise","planned":true,"acquired":true,"shares":64708,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price of the option is EUR 1.16392."}],"balance_after":524567,"source":{"system":"sec-edgar","filing":"0001193125-26-078718","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526078718/ownership.xml","form_type":"4"}},{"id":940542,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-14T02:49:18.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":30000,"derivative":{"exercise_price":13.3,"exercise_date":"2027-01-09","expiration_date":"2036-01-09","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001573785-26-000001","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000157378526000001/primary_doc.xml","form_type":"4"}},{"id":942368,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option (right to buy)","published_at":"2026-01-10T00:34:21.000Z","date":"2026-01-07","kind":"grant","planned":true,"acquired":true,"shares":364000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares underlying the option will vest on Janaury 2, 2027, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":364000,"derivative":{"exercise_price":35.45,"expiration_date":"2036-01-07","underlying":"Ordinary Shares","underlying_shares":364000},"source":{"system":"sec-edgar","filing":"0001193125-26-009272","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526009272/ownership.xml","form_type":"4"}},{"id":942367,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-01-10T00:34:21.000Z","date":"2026-01-07","kind":"grant","planned":true,"acquired":true,"shares":81000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents RSUs, each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, subject to the Reporting Person's continued service through each such date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each RSU was granted on January 7, 2026 for no consideration."}],"balance_after":459859,"source":{"system":"sec-edgar","filing":"0001193125-26-009272","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526009272/ownership.xml","form_type":"4"}},{"id":942366,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-01-10T00:34:21.000Z","date":"2026-01-07","kind":"sale","planned":true,"acquired":false,"shares":11582,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents pre-arranged sale of shares by the Reporting Person solely to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units (RSUs) pursuant to sell-to-cover agreement entered into with the Issuer. The sale does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.24 to $35.59 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":378859,"source":{"system":"sec-edgar","filing":"0001193125-26-009272","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526009272/ownership.xml","form_type":"4"}},{"id":1093930,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-03T12:13:15.000Z","date":"2025-07-01","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":80000,"derivative":{"exercise_price":5.75,"exercise_date":"2026-07-01","expiration_date":"2035-07-01","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001654954-25-007738","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495425007738/section16.xml","form_type":"4"}},{"id":1117964,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-09T20:42:59.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The entire option award shall vest on the earlier of:  (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date."}],"balance_after":22000,"derivative":{"exercise_price":4.44,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001415889-25-016283","document":"form4-06092025_080644.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588925016283/form4-06092025_080644.xml","form_type":"4"}},{"id":1188942,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-03-28T21:15:18.000Z","date":"2025-03-26","kind":"exercise","planned":false,"acquired":false,"shares":38394,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each RSU represents a contingent right to receive one ordinary share."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the BCA. The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date. The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Upon grant, all of the RSUs were fully-vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Upon grant, all of the RSUs were fully-vested."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":38394},"source":{"system":"sec-edgar","filing":"0000950170-25-046934","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025046934/ownership.xml","form_type":"4"}},{"id":1188941,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-03-28T21:15:18.000Z","date":"2025-03-26","kind":"grant","planned":false,"acquired":true,"shares":38394,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each RSU represents a contingent right to receive one ordinary share."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the BCA. The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date. The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Upon grant, all of the RSUs were fully-vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Upon grant, all of the RSUs were fully-vested."}],"balance_after":38394,"derivative":{"underlying":"Ordinary Shares","underlying_shares":38394},"source":{"system":"sec-edgar","filing":"0000950170-25-046934","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025046934/ownership.xml","form_type":"4"}},{"id":1188940,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2025-03-28T21:15:18.000Z","date":"2025-03-26","kind":"sale","planned":false,"acquired":false,"shares":12258,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Ordinary shares sold to satisfy tax withholding obligation arising upon the vesting of restricted stock units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These shares were sold in multiple transactions at a price ranging from $22.88 to $23.22 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities Exchange Comission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":390441,"source":{"system":"sec-edgar","filing":"0000950170-25-046934","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025046934/ownership.xml","form_type":"4"}},{"id":1188939,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2025-03-28T21:15:18.000Z","date":"2025-03-26","kind":"exercise","planned":false,"acquired":true,"shares":38394,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":402699,"source":{"system":"sec-edgar","filing":"0000950170-25-046934","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025046934/ownership.xml","form_type":"4"}},{"id":1188938,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2025-03-28T21:15:18.000Z","date":"2025-03-26","kind":"grant","planned":false,"acquired":true,"shares":30992,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects ordinary shares issued to the Reporting Person on March 26, 2025 as earnout shares pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the \"BCA\"). The BCA provided that certain shareholders would receive additional ordinary shares of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of November 22, 2022, the date of closing under the BCA (the \"Closing Date\"). The Reporting Person's right to receive the earnout shares became fixed and irrevocable on the Closing Date."}],"balance_after":364305,"source":{"system":"sec-edgar","filing":"0000950170-25-046934","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025046934/ownership.xml","form_type":"4"}},{"id":1308335,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option (right to buy)","published_at":"2025-01-07T22:21:22.000Z","date":"2025-01-06","kind":"grant","planned":false,"acquired":true,"shares":670467,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares underlying the option will vest on January 6, 2026, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":670467,"derivative":{"exercise_price":25.85,"expiration_date":"2035-01-06","underlying":"Ordinary Shares","underlying_shares":670467},"source":{"system":"sec-edgar","filing":"0000950170-25-003022","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025003022/ownership.xml","form_type":"4"}},{"id":1308334,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2025-01-07T22:21:22.000Z","date":"2025-01-07","kind":"grant","planned":false,"acquired":true,"shares":123529,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represenets restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, subject to the Reporting Person's continued service through each such date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU was granted on January 7, 2025 for no consideration."}],"balance_after":123529,"source":{"system":"sec-edgar","filing":"0000950170-25-003022","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025003022/ownership.xml","form_type":"4"}},{"id":1310496,"issuer":{"id":5028,"kind":"organization","name":"Silence Therapeutics plc"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2025-01-06T21:15:20.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":48000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in equal monthly installments over a three-year period measured from one month following January 2, 2025, subject to the Reporting Person's continuous service as of each applicable vesting date."}],"balance_after":48000,"derivative":{"exercise_price":2.4,"expiration_date":"2035-01-02","underlying":"Ordinary Shares","underlying_shares":48000},"source":{"system":"sec-edgar","filing":"0001415889-25-000749","document":"form4-01062025_040115.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479615/000141588925000749/form4-01062025_040115.xml","form_type":"4"}},{"id":1334916,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-12-13T00:54:37.000Z","date":"2024-12-10","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":100000,"derivative":{"exercise_price":5.94,"exercise_date":"2025-12-10","expiration_date":"2034-12-10","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001654954-24-015472","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495424015472/section16.xml","form_type":"4"}},{"id":1387655,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Warrant (right to buy)","published_at":"2024-10-11T21:01:08.000Z","date":"2024-10-09","kind":"gift","planned":false,"acquired":false,"shares":15000,"price":11.5,"value":172500.0,"ownership":{"direct":true},"balance_after":85000,"derivative":{"exercise_price":11.5,"exercise_date":"2022-12-22","expiration_date":"2027-11-23","underlying":"Ordinary Shares","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000950170-24-114388","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017024114388/ownership.xml","form_type":"4"}},{"id":1398468,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-27T20:20:18.000Z","date":"2024-03-26","kind":"grant","planned":false,"acquired":true,"shares":33986,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"This option award represents an equity security previously reported on the reporting person's Form 3, which was acquired through an exempt transaction with the Issuer prior to the Issuer registering a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended. It is reported herein as a transaction pursuant to Rule 16a-2(a)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on April 26, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":33986,"derivative":{"exercise_price":8.39,"expiration_date":"2034-03-25","underlying":"Common Stock","underlying_shares":33986},"source":{"system":"sec-edgar","filing":"0001415889-24-024042","document":"form4-09272024_080914.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588924024042/form4-09272024_080914.xml","form_type":"4"}},{"id":1398467,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-27T20:20:18.000Z","date":"2024-09-25","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The entire option award shall vest on the earlier of:  (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date."}],"balance_after":15000,"derivative":{"exercise_price":18,"expiration_date":"2034-09-24","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001415889-24-024042","document":"form4-09272024_080914.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588924024042/form4-09272024_080914.xml","form_type":"4"}},{"id":1425653,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2024-08-22T20:30:12.000Z","date":"2024-08-20","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":16.27,"value":81350.0,"ownership":{"direct":true},"balance_after":209784,"source":{"system":"sec-edgar","filing":"0000950170-24-099871","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017024099871/ownership.xml","form_type":"4"}},{"id":1438311,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"other":false}}],"security":"Warrant","published_at":"2024-08-08T23:42:23.000Z","date":"2024-08-08","kind":"purchase","planned":false,"acquired":true,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":". On August 8, 2024, as part of a private placement of the Issuer's securities, the Reporting Person purchased shares of the Issuer's common stock (\"Shares\") and a pre-funded warrant to purchase Shares, along with a warrant to purchase Shares, pursuant to the terms of a Securities Purchase Agreement, dated August 6, 2024, by and among the Issuer, Reporting Person and certain other accredited investors. The purchase price for each Share and accompanying warrant (reported in Table II) is $3.00. The purchase price for each pre-funded warrant and accompanying warrant (reported in Table II) is $2.99."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The warrant will expire on the earlier of (i) thirty (30) trading days following the date of the Issuer's initial public announcement of topline data from its Phase 3 LEVEL Study (LEVosimendan to Improve Exercise Limitation in PH-HFpEF Patients) ( NCT05983250 ) (the \"Topline Data Announcement\"); (ii) proportionally upon the exercise of the Reporting Person's pre-funded warrant  issued on August 8, 2024, if such exercise is prior to the Topline Data Announcement; and (iii) August 8, 2029."}],"balance_after":25000,"derivative":{"exercise_price":4.5,"exercise_date":"2024-08-08","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001654954-24-010192","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495424010192/section16.xml","form_type":"4"}},{"id":1438310,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"other":false}}],"security":"Pre-Funded Warrant","published_at":"2024-08-08T23:42:23.000Z","date":"2024-08-08","kind":"purchase","planned":false,"acquired":true,"shares":47500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":". On August 8, 2024, as part of a private placement of the Issuer's securities, the Reporting Person purchased shares of the Issuer's common stock (\"Shares\") and a pre-funded warrant to purchase Shares, along with a warrant to purchase Shares, pursuant to the terms of a Securities Purchase Agreement, dated August 6, 2024, by and among the Issuer, Reporting Person and certain other accredited investors. The purchase price for each Share and accompanying warrant (reported in Table II) is $3.00. The purchase price for each pre-funded warrant and accompanying warrant (reported in Table II) is $2.99."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The pre-funded warrant has no expiration date."}],"balance_after":47500,"derivative":{"exercise_price":0.01,"exercise_date":"2024-08-08","underlying":"Common Stock","underlying_shares":47500},"source":{"system":"sec-edgar","filing":"0001654954-24-010192","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495424010192/section16.xml","form_type":"4"}},{"id":1438309,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-08T23:42:23.000Z","date":"2024-08-08","kind":"purchase","planned":false,"acquired":true,"shares":2500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":". On August 8, 2024, as part of a private placement of the Issuer's securities, the Reporting Person purchased shares of the Issuer's common stock (\"Shares\") and a pre-funded warrant to purchase Shares, along with a warrant to purchase Shares, pursuant to the terms of a Securities Purchase Agreement, dated August 6, 2024, by and among the Issuer, Reporting Person and certain other accredited investors. The purchase price for each Share and accompanying warrant (reported in Table II) is $3.00. The purchase price for each pre-funded warrant and accompanying warrant (reported in Table II) is $2.99."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The aggregate number of shares of common stock previously reported as 608,645, but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024."}],"balance_after":2881,"source":{"system":"sec-edgar","filing":"0001654954-24-010192","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495424010192/section16.xml","form_type":"4"}},{"id":1470928,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2024-06-24T12:30:04.000Z","date":"2024-06-20","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":17.2617,"value":86308.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.115 to $17.60, inclusive. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, specific trade amounts and pricing within the range set forth in this footnote at which the transaction was effected."}],"balance_after":204784,"source":{"system":"sec-edgar","filing":"0000950170-24-076468","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017024076468/ownership.xml","form_type":"4"}},{"id":1693373,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option (right to buy)","published_at":"2024-01-03T22:14:52.000Z","date":"2024-01-01","kind":"grant","planned":false,"acquired":true,"shares":1039939,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option will vest on January 1, 2025, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":1039939,"derivative":{"exercise_price":11.17,"expiration_date":"2034-01-01","underlying":"Ordinary Shares","underlying_shares":1039939},"source":{"system":"sec-edgar","filing":"0000950170-24-001116","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017024001116/ownership.xml","form_type":"4"}},{"id":2237057,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-11T00:45:01.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":5000,"derivative":{"exercise_price":0.62,"exercise_date":"2023-06-09","expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001654954-22-008234","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495422008234/section16.xml","form_type":"4"}},{"id":2437210,"issuer":{"id":7814,"kind":"organization","name":"LISATA THERAPEUTICS, INC.","symbol":"LSTA"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-12T21:09:02.000Z","date":"2022-01-10","kind":"grant","acquired":true,"shares":65430,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 65,430 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 10, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 137,207 unvested restricted stock units."}],"balance_after":209753,"source":{"system":"sec-edgar","filing":"0001573785-22-000002","document":"wf-form4_164202172785612.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/320017/000157378522000002/wf-form4_164202172785612.xml","form_type":"4"}},{"id":2669467,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-06-15T20:34:17.000Z","date":"2021-06-11","kind":"exercise","acquired":false,"shares":512,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On June 10, 2021, the shareholders of Tenax Therapeutics, Inc. voted in favor of the conversion of all Series B Preferred Stock to Common Stock. Pursuant to this action, all Series B Preferred Stock owned by the Reporting Person converted automatically to shares of Common Stock on June 11, 2021."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"As described further in Note 1, above, the disposition of the Series B Preferred Stock and the acquisition of Common Stock occurred pursuant to an automatic conversion; as such, no consideration was paid to or payable by the Reporting Person pursuant to this transaction."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As described further in Note 1, above, the disposition of the Series B Preferred Stock and the acquisition of Common Stock occurred pursuant to an automatic conversion; as such, no consideration was paid to or payable by the Reporting Person pursuant to this transaction."}],"balance_after":0,"derivative":{"exercise_date":"2021-06-11","expiration_date":"2021-06-11","underlying":"Common Stock","underlying_shares":512000},"source":{"system":"sec-edgar","filing":"0001654954-21-006926","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495421006926/section16.xml","form_type":"4"}},{"id":2669466,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-15T20:34:17.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6250,"derivative":{"exercise_price":2,"exercise_date":"2022-06-10","expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0001654954-21-006926","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495421006926/section16.xml","form_type":"4"}},{"id":2669465,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-15T20:34:17.000Z","date":"2021-06-11","kind":"grant","acquired":true,"shares":512000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On June 10, 2021, the shareholders of Tenax Therapeutics, Inc. voted in favor of the conversion of all Series B Preferred Stock to Common Stock. Pursuant to this action, all Series B Preferred Stock owned by the Reporting Person converted automatically to shares of Common Stock on June 11, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As described further in Note 1, above, the disposition of the Series B Preferred Stock and the acquisition of Common Stock occurred pursuant to an automatic conversion; as such, no consideration was paid to or payable by the Reporting Person pursuant to this transaction."}],"balance_after":606645,"source":{"system":"sec-edgar","filing":"0001654954-21-006926","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495421006926/section16.xml","form_type":"4"}},{"id":2910141,"issuer":{"id":7814,"kind":"organization","name":"LISATA THERAPEUTICS, INC.","symbol":"LSTA"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-12T23:16:15.000Z","date":"2021-01-11","kind":"grant","acquired":true,"shares":37735,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 37,735 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 11, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 88,798 unvested restricted stock units."}],"balance_after":144323,"source":{"system":"sec-edgar","filing":"0001573785-21-000005","document":"wf-form4_161049336019219.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/320017/000157378521000005/wf-form4_161049336019219.xml","form_type":"4"}},{"id":3034877,"issuer":{"id":7814,"kind":"organization","name":"LISATA THERAPEUTICS, INC.","symbol":"LSTA"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-09-10T20:01:36.000Z","date":"2020-09-09","kind":"purchase","acquired":true,"shares":55525,"price":1.8,"value":99945.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transaction prices ranging from $1.74 to $1.84, inclusive. The reporting person undertakes to provide Caladrius Biosciences, Inc., any security holder of Caladrius Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 51,063 shares of unvested restricted stock units."}],"balance_after":106588,"source":{"system":"sec-edgar","filing":"0001573785-20-000017","document":"wf-form4_159976808251973.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/320017/000157378520000017/wf-form4_159976808251973.xml","form_type":"4"}},{"id":3061077,"issuer":{"id":7814,"kind":"organization","name":"LISATA THERAPEUTICS, INC.","symbol":"LSTA"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-08-12T13:21:26.000Z","date":"2020-07-28","kind":"grant","acquired":true,"shares":51063,"price":2.35,"value":119998.05,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 51,063 shares of restricted stock units granted under the 2018 Equity Incentive Compensation Plan. The shares of restricted stock units will vest in annual installments over a three-year period with the initial vesting on July 28, 2021."}],"balance_after":51063,"source":{"system":"sec-edgar","filing":"0001573785-20-000014","document":"wf-form4_159723846932411.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/320017/000157378520000014/wf-form4_159723846932411.xml","form_type":"4"}}]}